> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cambridge-derived brain health company Prema Cognition closes oversubscribed funding round to advance early dementia detection
- URL: https://med-techinsights.com/cambridge-derived-brain-health-company-prema-cognition-closes-oversubscribed-funding-round-to-advance-early-dementia-detection/
- Published: 2026-05-18T14:29:20.000Z
- Updated: 2026-10-22T07:54:34.000Z
- Description: Prema Cognition, a digital health company developing the novel technology PREMAZ for the early detection of dementia, has closed an oversubscribed funding round of 550,000 GBP, led by SFC Capital. The company initially set out to raise 500k, ultimately exceeding its target. Prema says the funding wi
- Author: Oliver Johnson
- Tags: Digital Health & AI, News

[**Prema Cognition**](https://www.premaz.org/?ref=med-techinsights.com), a digital health company developing the novel technology PREMAZ for the early detection of dementia, has closed an oversubscribed funding round of 550,000 GBP, led by [**SFC Capital**](https://sfccapital.com/?ref=med-techinsights.com). The company initially set out to raise 500k, ultimately exceeding its target.

Prema says the funding will support the expansion of clinical datasets to further validate the technology, alongside progress towards regulatory pathways and broader deployment across healthcare and research settings.

The team is developing a digital cognitive testing platform designed to detect subtle changes in memory that can appear decades before a formal dementia diagnosis. It’s memory test, PREMAZ, identifies at-risk patients years earlier than existing tools according to the company.

“Many new therapies for Alzheimer’s disease and related conditions are designed to work at the earliest stages of the disease process,” said Dr. Julia Cooney, Founder and CEO of Prema Cognition. “However, most existing cognitive tests detect impairment only once irreversible damage has already occurred. Our test shifts the detection window years earlier, providing a far more sensitive way of identifying subtle changes in memory.”

Prema Cognition is supported by a scientific and clinical advisory group, including Dr. Helena Gellersen, a postdoctoral researcher at the University of Cambridge whose work on memory precision underpins the technology, and Dr. Ravi Badge, consultant orthopaedic surgeon and sports medicine specialist.

Prema says that alongside SFC Capital, the round brings together an experienced group of angel investors spanning pharma, biotech, enterprise software, and longevity, including follow-on investment from existing backers and new strategic angels.

This group includes Jasbir Singh, a Basel-based serial entrepreneur with 35+ years of experience across enterprise software and life sciences; Steve Hartman, former general counsel and head of M&A at an NYSE-listed life sciences leader; Keith Williams, a biotech entrepreneur with 30+ years of experience in pharma and SaaS; and Yin Chao Lee, a Singapore-based longevity investor focused on preventative healthcare technologies.